InflaRx N.V. (IFRX)

Market Cap	328.63M +427.3%
Revenue (ttm)	-11,540 -82.3%
Net Income	-44.72M
EPS	-0.54
Shares Out	147.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	610,389
Open	2.280
Previous Close	2.270
Day's Range	2.210 - 2.370
52-Week Range	0.798 - 2.949
Beta	2.51
Analysts	Strong Buy
Price Target	7.96 (+256.95%)
Earnings Date	Aug 6, 2026

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2017
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: IFRX
• Website: https://www.inflarx.de

Financial Performance

In 2025, InflaRx's revenue was 29,331, a decrease of -82.31% compared to the previous year's 165,789. Losses were -45.63 million, -0.93% less than in 2024.

Financial numbers in EUR

Analyst Summary

According to 8 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price target is $7.96, which is an increase of 256.95% from the latest price.

Price Target

$7.96

(256.95% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 29, 2026

Data Sources Report a data error